News - Rigel Pharmaceuticals

Filter

Current filters:

Rigel Pharmaceuticals

Popular Filters

Rigel Pharma to focus on three leading clinical programs

05-09-2013

USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) today announced its plans to focus the company's resources…

DermatologicalsfostamatinibManagementOphthalmicsPharmaceuticalR333R348ResearchRigel Pharmaceuticals

Rigel shares fall as asthma compound fails to meet primary endpoint

27-08-2013

Shares of USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) fell 10% to $3.27 in morning trading yesterday…

AstraZenecafostamatinibNorth AmericaPharmaceuticalResearchRespiratory and PulmonaryRigel Pharmaceuticals

AstraZeneca returns fostamatinib program rights to Rigel

04-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Rigel Pharmaceuticals (Nasdaq: RIGL) today…

Anti-Arthritics/RheumaticsAstraZenecafostamatinibLicensingPharmaceuticalResearchRigel Pharmaceuticals

AstraZeneca presents mixed data on fostamatinib in RA

13-12-2012

Shares of Anglo-Swedish drug major AstraZeneca (LSE: AZN) fell 2.1% to $47.88 in premarket US trading…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyfostamatinibPharmaceuticalResearchRigel Pharmaceuticals

AstraZeneca gains rights to Rigel's asthma candidate R256

20-06-2012

Anglo Swedish drug major AstraZeneca (LSE: AZN) and signed an exclusive global license accord with USA-based…

AstraZenecafostamatinibLicensingPharmaceuticalR256Respiratory and PulmonaryRigel Pharmaceuticals

Pfizer returns asthma drug candidate rights to Rigel Pharma; latter narrows losses

09-05-2011

As a result of global drugs behemoth Pfizer’s (NYSE: PFE) decision to exit R&D in the field of allergy…

FinancialLicensingPfizerPharmaceuticalRespiratory and PulmonaryRigel Pharmaceuticals

Back to top